ScreenerHero

TNYA Tenaya Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tenayatherapeutics.com
0.5334USD-2.40%Mkt Cap: 119.60M $P/E: —

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap119.60M USD
Enterprise Value48.41M USD
Revenue (TTM)1.33M USD
Gross Profit1.33M USD
Net Income (TTM)-90.60M USD
Revenue/Share0.0070 USD
Last Price0.5334 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees70
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.39
PEG—
EV/EBITDA-0.64
EV/Revenue36.26
P/S91.79
P/B1.12
EPS (TTM)-0.50
EPS (Forward)-0.39
52W Range
0.53000% of range2.350
52W High2.350 USD
52W Low0.5300 USD
Profitability
Gross Margin100.00%
Oper. Margin-1882.79%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.50%
ROA-61.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-68.26M USD
CapEx (TTM)618.00K USD
FCF Margin-2441.99%
FCF Yield-27.26%
Net Debt-74.14M USD
Net Debt/EBITDA0.98
Balance Sheet
Debt/Equity0.09
Current Ratio4.52
Quick Ratio4.13
Book Value/Sh0.49 USD
Cash/Share0.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.200 USD
Upside (mean)+499.9%
Target Range2.000 USD – 5.000 USD
2.000+499.9% to mean5.000
# Analysts5
Ownership
Shares Out.224.23M
Float211.72M
Insiders0.48%
Institutions48.83%
Short Interest
Short Ratio11.7d
Short % Float12.43%
Short % Out.9.65%
Shares Short21.64M
Short (prev mo.)21.10M
Technical
SMA 500.6859 (-22.2%)
SMA 2000.7381 (-27.7%)
Beta2.88
S&P 52W Chg16.45%
Avg Vol (30d)2.52M
Avg Vol (10d)3.24M
Technical Indicators
RSI (14)25.4
MACD-0.0425
MACD Signal-0.0353
MACD Hist.-0.0072
BB Upper0.7259 USD
BB Middle0.6237 USD
BB Lower0.5214 USD
BB Width32.78%
ATR (14)0.0348 USD
Vol Ratio (20d)1.36x